Developer docs
API playgroundTry for free, no card

Search company profiles

Kantify

Full company profile

uuid000b2rb

Namestring
Kantify
Legal namestring
Kantify
Websiteurl
kantify.com
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Kantify is a Belgian biotech company founded in 2016 and headquartered in Brussels, operating a remote-first team of 1–10 employees based primarily in Belgium and France. Its core product is Sapian, a proprietary AI-driven small molecule discovery engine that uses probabilistic inference — rather than structure-based docking or physical high-throughput screening — to predict protein-ligand interactions across the entire eukaryotic proteome. Sapian is organized into Sapian.Target (novel protein target discovery) and Sapian.Hit (polypharmacological new chemical entity identification), with built-in safety-by-design features including hERG, ADMETox (BBB, DILI), and IP-clean chemotype selection. The platform routinely screens 13.6 billion compounds per day, a 10,000-fold scale advantage over average pharma HTS campaigns, and reports partner hit rates of 10%–90% versus an industry average below 0.1%.

Kantify monetizes Sapian through an enterprise, project-based partnership model: prospective customers (top-10 global biopharma companies, leading academic and hospital research labs, and patient organizations focused on rare diseases) submit biological targets; Sapian performs in silico virtual screening and optimization; and partners conduct wet-lab validation using their own infrastructure. The funnel begins with non-binding, confidential feasibility analyses and progresses into paid discovery collaborations. Customers disclosed in source materials include Johns Hopkins University School of Medicine, Nanyang Technological University, Institut Bergonié, INSERM, CNRS, I-Stem, and the European Commission (DREAMS AI project). Revenue is also supplemented by patient-organization grants (e.g., INCITE Foundation) and EU program funding.

The company positions itself as a 'post-docking era' pioneer, differentiating on the ability to address 'undruggable' targets without 3D structures or known modulators, with disclosed outcomes including a 132x hit-rate improvement in the Johns Hopkins prostate cancer program, full tumor growth arrest in vivo without notable toxicity, and compression of typical 24-month target-to-validation timelines to 4 months in the liposarcoma program. Founder-CEO Ségolène Martin leads the organization, supported by COO Nicolas Maignan and Scientific Advisor Dr. Eckhard von Keutz (former VP at Bayer Pharmaceuticals). No external funding rounds, revenue figures, or patent portfolio details are disclosed in the available source material.

Short descriptiontext

Kantify is a Belgian AI biotech founded in 2016 that operates Sapian, a probabilistic-inference small molecule discovery engine for undruggable targets, serving top global biopharma companies, academic and hospital research labs, and rare-disease patient organizations through project-based partnerships.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBrussels, Belgium
HQ citystring
Brussels
HQ countrystring
Belgium
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI drug discovery, small molecule discovery, computational chemistry, target identification, proteome screening
Industry3 codes
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Computer Programming Services7371
Product category
AI Drug Discovery Platform
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1AI Drug Discovery Services
TypeSubscription Recurring
Description

Kantify provides AI-powered drug discovery services through its Sapian platform. Partners provide biological targets, and Sapian conducts virtual screening and optimization. The company follows a partnership model where wet lab validation is conducted by partners using their existing testing infrastructure. Revenue is generated through project-based collaborations with pharmaceutical companies, academic institutions, and patient organizations.

kantify.com
2Feasibility Analysis Services
TypeProfessional Services
Description

Non-binding and confidential feasibility analyses are offered for therapeutic targets before any pilot engagement, potentially leading to paid discovery projects.

kantify.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 record
1Sapian
Description

AI-driven small molecule discovery engine for undruggable targets, capable of screening billions of compounds per day and predicting protein-ligand interactions across the eukaryotic proteome.

kantify.com
Core offering1 text field

Kantify develops and operates Sapian, a universal AI-driven small molecule discovery engine that uses probabilistic inference to predict protein-ligand interactions across the entire eukaryotic proteome. It identifies novel, IP-clean chemotypes for previously undruggable therapeutic targets, routinely screening 13.6 billion compounds per day without requiring crystal structures or known modulators. The platform delivers project-based virtual screening, hit optimization, and safety prediction services to pharmaceutical, academic, and patient-organization partners.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • Screens 13 billion compounds per day (10,000x faster than average HTS)
+6 more records
Product overview1 text field

Kantify operates as a single unified AI drug discovery platform called Sapian, which consists of integrated modules for target discovery (Sapian.Target) and hit discovery (Sapian.Hit). Sapian uses probabilistic AI inference to overcome undruggable targets without requiring crystal structures, screening billions of compounds to identify novel, IP-clean chemotypes. The platform also offers a scientific content series called 'Behind the Pill' that publishes Sapian-generated target predictions for established drugs. Kantify also developed AI models for medical imaging analysis (diabetic retinopathy detection) and cardiac arrhythmia prediction (atrial fibrillation), though these are historical capabilities rather than current product offerings.

Product and service4 records
1Sapian
CategoryAI Drug Discovery Platform
Description

Universal AI-driven small molecule discovery engine that uses probabilistic inference to predict protein-ligand interactions across the entire eukaryotic proteome, identifying novel IP-clean chemotypes for undruggable therapeutic targets. Screens 13.6 billion compounds per day without requiring crystal structures or known modulators.

2Sapian.Target
CategoryAI Target Discovery Module
Description

Target discovery algorithm within Sapian that identifies multiple novel protein targets driving disease growth and metastasis for experimental validation.

3Sapian.Hit
CategoryAI Hit Discovery Module
Description

Hit discovery algorithm within Sapian that identifies polypharmacological new chemical entities predicted to modulate specified targets of interest by screening virtual libraries.

4AI Drug Discovery Partnership Services
CategoryDrug Discovery Services
Description

Project-based virtual screening and lead optimization engagements in which partners submit biological targets, Sapian conducts massive-scale virtual search and optimization, and partners perform wet-lab validation using their existing infrastructure.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership13 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-22
Description

Dr. Maya Jeitany's lab conducted joint execution of parallel target discovery and hit discovery using Sapian for liposarcoma. Target validation and hit validation of Sapian predictions resulted in first in vivo-ready candidate.

2Institut Bergonié
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-22
Description

Independently validated candidates predicted by Sapian through in vitro and in vivo assays under Professor Antoine Italiano's leadership. Reproduced core signal, evaluated additional molecules, and conducted in vivo validation demonstrating increased overall survival in mouse CDX models.

kantify.com
Strategic tierSupportingTypeTechnology or IntegrationAnnounced on2025-10-22
Description

Complementary biotech company that performed off target toxicity testing on iPSC-derived organoids through its state-of-the-art robotics platform as part of the liposarcoma program.

Strategic tierSupportingTypeTechnology or IntegrationAnnounced on2025-10-22
Description

Used its dedicated AI technology to collect and rank different IP and market positioning characteristics of Kantify's repurposable candidates in the liposarcoma program.

5CNRS
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

Ubiquitin-like protein target discovery project resulting in first-in-class candidate after only 15 compounds tested in total with best candidate at 2μM potency.

kantify.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Cardiovascular hERG cardiotoxicity prediction validation. Showed near 95% balanced accuracy in predicting hERG toxicity on unseen compounds with high chemical diversity.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Limb-Girdle Muscular Dystrophies (LGMD) research identifying multiple novel druggable targets. Validated targets using siRNA silencing in iPSC-derived cellular models of the disease, opening road to targeted therapies for LGMD patients.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-12-12
Description

Collaboration with Dr. Perera's lab using Sapian to discover novel drugs for metastatic castration-resistant prostate cancer. Identified small molecule candidates through virtual screening, with successful in vivo validation showing full tumor growth arrest without notable toxicity. Resulted in identification of four novel entities combating prostate cancer.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-11-29
Description

Selected by the European Commission to perform unprecedented research project on rare diseases and AI. The DREAMS AI project focuses on tackling 5 rare diseases using AI-powered drug discovery.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

Orphan ion channel target validation project resulting in successful de-orphanization of target through first-in-class candidate with 2.2μM potency. SAPian selected 19 compounds from 8 million library yielding 2 hits.

Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2021-07-22
Description

Joined the European Biotechnology Network dedicated to facilitating international cooperation and bringing together European research groups, universities, SMEs, and large organizations working in biotechnology and life sciences.

Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2021-05-10
Description

Joined Data-driven Advanced Therapeutics Accelerator managed by Stevenage Bioscience Catalyst, supporting growth and networking in the advanced therapies ecosystem.

Strategic tierSupportingTypeTechnology or Integration
Description

Kantify uses Mcule's compound sourcing platform to leverage data for better hit prediction, combining AI-powered virtual screening with efficient compound procurement.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

XtalPi combines AI, quantum physics, and robotics for small molecule discovery and crystallization prediction, with a strong Asia-Pacific footprint and growing pharma partnerships in adjacent AI-driven chemistry.

TypeDirect peer
Description

Recursion is a direct peer applying AI/ML to high-content biology and chemistry, with its own clinical pipeline plus major pharma partnerships (Roche-Genentech, Bayer), competing for similar enterprise platform deals.

TypeDirect peer
Description

Schrödinger provides physics-based and AI-augmented computational chemistry platforms (LiveDesign) used by pharma for hit identification and lead optimization, serving as a benchmark for the enterprise computational drug discovery category Kantify competes in.

TypeDirect peer
Description

Atomwise is the closest direct peer: an AI-native small molecule discovery company whose AtomNet platform screens ultra-large virtual libraries for hit identification, mirroring Kantify's Sapian workflow and target customer base of pharma and academic partners.

5Isomorphic Labs
TypeDirect peer
Description

Isomorphic Labs (Alphabet) is a direct peer using deep learning for drug design, with major pharma alliances (Eli Lilly, Novartis) and ambitions to industrialize AI-driven small molecule discovery.

TypeDirect peer
Description

Insilico Medicine is a direct peer using generative AI and deep learning for target identification and small molecule design, with an internal pipeline plus pharma collaborations spanning oncology, fibrosis, and rare diseases.

TypeDirect peer
Description

BenevolentAI combines a biomedical knowledge graph with machine learning for target discovery and small molecule design, addressing the same undruggable-target and rare-disease use cases as Sapian.

TypeDirect peer
Description

Iambic (formerly Entos) is an early-stage direct peer building AI models for small molecule design and ADMET prediction, with comparable ambitions around high-throughput virtual screening and partner-led validation.

TypeDirect peer
Description

Exscientia is a direct peer offering AI-driven end-to-end small molecule drug design, including hit discovery, lead optimization, and partnered clinical assets, competing for the same top-10 biopharma platform deals that Kantify targets.

TypeEmerging player
Description

Genesis Therapeutics is an emerging AI-first small molecule design company using generative models for hit discovery, with a pipeline and pharma collaborations that overlap with Kantify's target identification and lead generation value proposition.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Kantify

AI Drug Discovery Platformkantify.com

Kantify is a Belgian AI biotech founded in 2016 that operates Sapian, a probabilistic-inference small molecule discovery engine for undruggable targets, serving top global biopharma companies, academic and hospital research labs, and rare-disease patient organizations through project-based partnerships.

What Kantify does

Kantify is a Belgian biotech company founded in 2016 and headquartered in Brussels, operating a remote-first team of 1–10 employees based primarily in Belgium and France. Its core product is Sapian, a proprietary AI-driven small molecule discovery engine that uses probabilistic inference — rather than structure-based docking or physical high-throughput screening — to predict protein-ligand interactions across the entire eukaryotic proteome. Sapian is organized into Sapian.Target (novel protein target discovery) and Sapian.Hit (polypharmacological new chemical entity identification), with built-in safety-by-design features including hERG, ADMETox (BBB, DILI), and IP-clean chemotype selection. The platform routinely screens 13.6 billion compounds per day, a 10,000-fold scale advantage over average pharma HTS campaigns, and reports partner hit rates of 10%–90% versus an industry average below 0.1%.

Kantify monetizes Sapian through an enterprise, project-based partnership model: prospective customers (top-10 global biopharma companies, leading academic and hospital research labs, and patient organizations focused on rare diseases) submit biological targets; Sapian performs in silico virtual screening and optimization; and partners conduct wet-lab validation using their own infrastructure. The funnel begins with non-binding, confidential feasibility analyses and progresses into paid discovery collaborations. Customers disclosed in source materials include Johns Hopkins University School of Medicine, Nanyang Technological University, Institut Bergonié, INSERM, CNRS, I-Stem, and the European Commission (DREAMS AI project). Revenue is also supplemented by patient-organization grants (e.g., INCITE Foundation) and EU program funding.

The company positions itself as a 'post-docking era' pioneer, differentiating on the ability to address 'undruggable' targets without 3D structures or known modulators, with disclosed outcomes including a 132x hit-rate improvement in the Johns Hopkins prostate cancer program, full tumor growth arrest in vivo without notable toxicity, and compression of typical 24-month target-to-validation timelines to 4 months in the liposarcoma program. Founder-CEO Ségolène Martin leads the organization, supported by COO Nicolas Maignan and Scientific Advisor Dr. Eckhard von Keutz (former VP at Bayer Pharmaceuticals). No external funding rounds, revenue figures, or patent portfolio details are disclosed in the available source material.

Kantify firmographics

Firmographics
Name
Kantify
Legal name
Kantify
Website
https://kantify.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Short description
Kantify is a Belgian AI biotech founded in 2016 that operates Sapian, a probabilistic-inference small molecule discovery engine for undruggable targets, serving top global biopharma companies, academic and hospital research labs, and rare-disease patient organizations through project-based partnerships.
Ownership category
akta.pro rank

Kantify industry classification

Industry
Product category
AI Drug Discovery Platform
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Computer Programming Services (7371)
akta.pro industry
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

Keywords

  • AI drug discovery
  • Small molecule discovery
  • Computational chemistry
  • Target identification
  • Proteome screening

Where Kantify is headquartered

Location

Headquarters

HQ city
Brussels
HQ country
Belgium
HQ region
Europe

Offices1 record

Markets served

Kantify business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. AI Drug Discovery Services: Kantify provides AI-powered drug discovery services through its Sapian platform. Partners provide biological targets, and Sapian conducts virtual screening and optimization. The company follows a partnership model where wet lab validation is conducted by partners using their existing testing infrastructure. Revenue is generated through project-based collaborations with pharmaceutical companies, academic institutions, and patient organizations.
  2. Feasibility Analysis Services: Non-binding and confidential feasibility analyses are offered for therapeutic targets before any pilot engagement, potentially leading to paid discovery projects.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Kantify product offering

Product offering

Core offering

Kantify develops and operates Sapian, a universal AI-driven small molecule discovery engine that uses probabilistic inference to predict protein-ligand interactions across the entire eukaryotic proteome. It identifies novel, IP-clean chemotypes for previously undruggable therapeutic targets, routinely screening 13.6 billion compounds per day without requiring crystal structures or known modulators. The platform delivers project-based virtual screening, hit optimization, and safety prediction services to pharmaceutical, academic, and patient-organization partners.

Product overview

Kantify operates as a single unified AI drug discovery platform called Sapian, which consists of integrated modules for target discovery (Sapian.Target) and hit discovery (Sapian.Hit). Sapian uses probabilistic AI inference to overcome undruggable targets without requiring crystal structures, screening billions of compounds to identify novel, IP-clean chemotypes. The platform also offers a scientific content series called 'Behind the Pill' that publishes Sapian-generated target predictions for established drugs. Kantify also developed AI models for medical imaging analysis (diabetic retinopathy detection) and cardiac arrhythmia prediction (atrial fibrillation), though these are historical capabilities rather than current product offerings.

Differentiator

Problem solved

Functional benefit

Brands

  • Sapian: AI-driven small molecule discovery engine for undruggable targets, capable of screening billions of compounds per day and predicting protein-ligand interactions across the eukaryotic proteome.

Products and services

  • Sapian Universal AI-driven small molecule discovery engine that uses probabilistic inference to predict protein-ligand interactions across the entire eukaryotic proteome, identifying novel IP-clean chemotypes for undruggable therapeutic targets. Screens 13.6 billion compounds per day without requiring crystal structures or known modulators.
  • Sapian.Target Target discovery algorithm within Sapian that identifies multiple novel protein targets driving disease growth and metastasis for experimental validation.
  • Sapian.Hit Hit discovery algorithm within Sapian that identifies polypharmacological new chemical entities predicted to modulate specified targets of interest by screening virtual libraries.
  • AI Drug Discovery Partnership Services Project-based virtual screening and lead optimization engagements in which partners submit biological targets, Sapian conducts massive-scale virtual search and optimization, and partners perform wet-lab validation using their existing infrastructure.

Quantifiable outcome

  • Screens 13 billion compounds per day (10,000x faster than average HTS)
  • +6 more outcomes

Companies that use Kantify

Customer profile

Named customers7 records

Segments3 records

Ideal customer profiles3 records

Kantify technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature6 records

Kantify partnerships and signals

Strategic signal

Partnerships

13 partnerships are on record, tiered core and supporting.

  • Nanyang Technological UniversitycoreStrategic or Co-development Partner · 22 October 2025Dr. Maya Jeitany's lab conducted joint execution of parallel target discovery and hit discovery using Sapian for liposarcoma. Target validation and hit validation of Sapian predictions resulted in first in vivo-ready candidate.
  • Institut BergoniécoreStrategic or Co-development Partner · 22 October 2025Independently validated candidates predicted by Sapian through in vitro and in vivo assays under Professor Antoine Italiano's leadership. Reproduced core signal, evaluated additional molecules, and conducted in vivo validation demonstrating increased overall survival in mouse CDX models.
  • Rosebud BiosciencessupportingTechnology or Integration · 22 October 2025Complementary biotech company that performed off target toxicity testing on iPSC-derived organoids through its state-of-the-art robotics platform as part of the liposarcoma program.
  • Vibe BiosupportingTechnology or Integration · 22 October 2025Used its dedicated AI technology to collect and rank different IP and market positioning characteristics of Kantify's repurposable candidates in the liposarcoma program.
  • CNRScoreStrategic or Co-development Partner · 1 January 2025Ubiquitin-like protein target discovery project resulting in first-in-class candidate after only 15 compounds tested in total with best candidate at 2μM potency.
  • Université de NantescoreStrategic or Co-development Partner · 1 January 2024Cardiovascular hERG cardiotoxicity prediction validation. Showed near 95% balanced accuracy in predicting hERG toxicity on unseen compounds with high chemical diversity.
  • I-StemcoreStrategic or Co-development Partner · 1 January 2024Limb-Girdle Muscular Dystrophies (LGMD) research identifying multiple novel druggable targets. Validated targets using siRNA silencing in iPSC-derived cellular models of the disease, opening road to targeted therapies for LGMD patients.
  • Johns Hopkins University School of MedicinecoreStrategic or Co-development Partner · 12 December 2023Collaboration with Dr. Perera's lab using Sapian to discover novel drugs for metastatic castration-resistant prostate cancer. Identified small molecule candidates through virtual screening, with successful in vivo validation showing full tumor growth arrest without notable toxicity. Resulted in identification of four novel entities combating prostate cancer.
  • European CommissioncoreStrategic or Co-development Partner · 29 November 2023Selected by the European Commission to perform unprecedented research project on rare diseases and AI. The DREAMS AI project focuses on tackling 5 rare diseases using AI-powered drug discovery.
  • INSERM/IGF/Université de NantescoreStrategic or Co-development Partner · 1 January 2022Orphan ion channel target validation project resulting in successful de-orphanization of target through first-in-class candidate with 2.2μM potency. SAPian selected 19 compounds from 8 million library yielding 2 hits.
  • European Biotechnology NetworksupportingStrategic or Co-development Partner · 22 July 2021Joined the European Biotechnology Network dedicated to facilitating international cooperation and bringing together European research groups, universities, SMEs, and large organizations working in biotechnology and life sciences.
  • Stevenage Bioscience CatalystsupportingStrategic or Co-development Partner · 10 May 2021Joined Data-driven Advanced Therapeutics Accelerator managed by Stevenage Bioscience Catalyst, supporting growth and networking in the advanced therapies ecosystem.
  • MculesupportingTechnology or IntegrationKantify uses Mcule's compound sourcing platform to leverage data for better hit prediction, combining AI-powered virtual screening with efficient compound procurement.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Kantify competitors and assessment

Company assessment

Emerging players

  • XtalPi: XtalPi combines AI, quantum physics, and robotics for small molecule discovery and crystallization prediction, with a strong Asia-Pacific footprint and growing pharma partnerships in adjacent AI-driven chemistry.
  • Genesis Therapeutics: Genesis Therapeutics is an emerging AI-first small molecule design company using generative models for hit discovery, with a pipeline and pharma collaborations that overlap with Kantify's target identification and lead generation value proposition.

Direct peers

  • Recursion Pharmaceuticals: Recursion is a direct peer applying AI/ML to high-content biology and chemistry, with its own clinical pipeline plus major pharma partnerships (Roche-Genentech, Bayer), competing for similar enterprise platform deals.
  • Schrödinger: Schrödinger provides physics-based and AI-augmented computational chemistry platforms (LiveDesign) used by pharma for hit identification and lead optimization, serving as a benchmark for the enterprise computational drug discovery category Kantify competes in.
  • Atomwise: Atomwise is the closest direct peer: an AI-native small molecule discovery company whose AtomNet platform screens ultra-large virtual libraries for hit identification, mirroring Kantify's Sapian workflow and target customer base of pharma and academic partners.
  • Isomorphic Labs: Isomorphic Labs (Alphabet) is a direct peer using deep learning for drug design, with major pharma alliances (Eli Lilly, Novartis) and ambitions to industrialize AI-driven small molecule discovery.
  • Insilico Medicine: Insilico Medicine is a direct peer using generative AI and deep learning for target identification and small molecule design, with an internal pipeline plus pharma collaborations spanning oncology, fibrosis, and rare diseases.
  • BenevolentAI: BenevolentAI combines a biomedical knowledge graph with machine learning for target discovery and small molecule design, addressing the same undruggable-target and rare-disease use cases as Sapian.
  • Iambic: Iambic (formerly Entos) is an early-stage direct peer building AI models for small molecule design and ADMET prediction, with comparable ambitions around high-throughput virtual screening and partner-led validation.
  • Exscientia: Exscientia is a direct peer offering AI-driven end-to-end small molecule drug design, including hit discovery, lead optimization, and partnered clinical assets, competing for the same top-10 biopharma platform deals that Kantify targets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Kantify social profiles

Digital presence

Kantify financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Kantify leadership team

Management profile

Number of profiles

Profiles5 records

Kantify funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Kantify M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kantify

What does Kantify do?

Kantify develops and operates Sapian, a universal AI-driven small molecule discovery engine that uses probabilistic inference to predict protein-ligand interactions across the entire eukaryotic proteome. It identifies novel, IP-clean chemotypes for previously undruggable therapeutic targets, routinely screening 13.6 billion compounds per day without requiring crystal structures or known modulators. The platform delivers project-based virtual screening, hit optimization, and safety prediction services to pharmaceutical, academic, and patient-organization partners.

Is Kantify a public or private company?

Kantify is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Kantify founded?

Kantify was founded in 2016. It employs 11 to 50 people.

Where is Kantify based?

Kantify is headquartered in Brussels, Belgium, in the Europe region.

How does Kantify make money?

Two revenue lines are on record. AI Drug Discovery Services are the primary driver. The others are feasibility Analysis Services.

Who are Kantify's main competitors?

Emerging players on record are XtalPi and Genesis Therapeutics. Direct peers are Recursion Pharmaceuticals, Schrödinger, Atomwise, Isomorphic Labs, Insilico Medicine, BenevolentAI, Iambic and Exscientia.

Does Kantify have an API?

No public API is recorded for Kantify.

What industry is Kantify in?

Kantify's product category is AI Drug Discovery Platform. Its primary akta.pro industry code is HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening), with a secondary code of HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 541714 and its SIC code is 7371.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Innovation News NetworkAI joins the quest to find new treatments for rare neuromuscular diseasesBelgian AI company Kantify is partnering with French research institute I-Stem on the EU-funded DREAMS initiative to accelerate drug discovery for rare neuromuscular disorders. The project utilizes Kantify's Sapian AI platform combined with induced pluripotent stem cell models to identify shared therapeutic targets and repurpose existing approved drugs. The five-year research program aims to conclude by the end of 2028, focusing on basket trials to test potential treatments across multiple conditions.Cyprus MailAI joins the quest to find new treatments for rare diseasesKantify, a Belgian AI company, is using AI and stem cell models to identify treatments for five rare neuromuscular disorders in a five-year EU-funded DREAMS initiative. The project tests 2,700 approved drugs on patient-derived muscle cells, aiming to repurpose existing medicines. The initiative concludes in 2028, with basket trials proposed to speed up development.News-MedicaliXCells Biotechnologies joins international collaboration to evaluate chemotherapeutic toxicity in human organoidsiXCells Biotechnologies announced an international collaboration with Rosebud, Kantify, and Incite to evaluate off-target chemotherapeutic toxicities in patient-specific organoids. The project will initially focus on heart, liver, and kidney models, using patient-derived hiPSCs and AI-driven analysis to generate personalized toxicity profiles.BioSpaceKantify Reaches New Milestone in AI-Driven Drug Discovery: 10 Billion Molecules Analyzed Per Day and a Major Advance in a Rare CancerKantify, a Belgian AI biotechnology firm, announced that its Sapian platform can analyze 10 billion molecules per day, significantly advancing its capabilities in drug discovery. The platform recently enabled the discovery of a promising molecule for liposarcoma, a rare cancer, demonstrating its effectiveness in therapeutic research. The company has also established collaborations with major research institutions and a top pharmaceutical company.MedicalExpo e-MagazineKantify on Drug Discovery with AIKantify, a Belgian biotech startup founded in 2016, is using its proprietary AI platform Sapian™ to accelerate drug discovery for rare diseases, oncology, and neurology, presenting its findings at Forum Labo in Paris. The company has demonstrated measurable success, including identifying three promising drug candidates for castration-resistant prostate cancer from a screen of over 8 million compounds, and discovering 11 first-known activators for a previously resistant ion channel. In January 2025, Kantify publicly unveiled its drug discovery pipeline, which includes Project James—a partnership with AFM-Téléthon and European Union funding targeting five rare neuromuscular diseases.